Filanesib - CAS 885060-09-3
Catalog number:
885060-09-3
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
COA:
Inquire
Targets:
Ksp
Description:
Filanesib, also known as ARRY-520, is a synthetic, small molecule targeting the kinesin spindle protein (KSP) with potential antineoplastic activity. KSP inhibitor ARRY-520 specifically inhibits KSP (kinesin-5 or Eg5), resulting in activation of the spindle assembly checkpoint, induction of cell cycle arrest during the mitotic phase, and consequently cell death in tumor cells that are actively dividing.
Publictions citing BOC Sciences Products
  • >> More
Purity:
0.98
Appearance:
white solid powder
Synonyms:
ARRY-520; ARRY 520; ARRY520.
MSDS:
Inquire
Current Developer:
Array BioPharma.
1.First-in-human phase 1 study of filanesib (ARRY-520), a kinesin spindle protein inhibitor, in patients with advanced solid tumors.
LoRusso PM1, Goncalves PH, Casetta L, Carter JA, Litwiler K, Roseberry D, Rush S, Schreiber J, Simmons HM, Ptaszynski M, Sausville EA. Invest New Drugs. 2015 Apr;33(2):440-9. doi: 10.1007/s10637-015-0211-0. Epub 2015 Feb 17.
Purpose Filanesib (ARRY-520) is a highly selective, targeted inhibitor of kinesin spindle protein (KSP) inhibitor that induces mitotic arrest and subsequent tumor cell death. This first-in-human Phase 1 study evaluated dose-limiting toxicities (DLTs) and determined a maximum tolerated dose (MTD) for filanesib administered as a 1-h intravenous infusion on 2 treatment schedules in patients with advanced solid tumors. The pharmacokinetics (PK), pharmacodynamics and preliminary efficacy of filanesib were also evaluated. Methods Filanesib was administered on Day 1 of each 3-week cycle (Initial Schedule) or Days 1 and 2 of each 2-week cycle (Alternate Schedule). A standard 3 + 3 dose-escalation design was employed. An expansion cohort was conducted at the MTD of the Initial Schedule. Filanesib PK was evaluated in plasma (both schedules) and urine (Initial Schedule only). Monopolar spindle formation was evaluated in biopsies taken from patients in the expansion cohort.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Ksp Products


CAS 940929-33-9 SB-743921 HCl

SB-743921 HCl
(CAS: 940929-33-9)

SB-743921 is a synthetic small molecule with potential antineoplastic properties. SB-743921 selectively inhibits kinesin spindle protein (KSP), an important pro...

CAS 885060-09-3 Filanesib

Filanesib
(CAS: 885060-09-3)

Filanesib, also known as ARRY-520, is a synthetic, small molecule targeting the kinesin spindle protein (KSP) with potential antineoplastic activity. KSP inhibi...

CAS 845256-65-7 MK-0731

MK-0731
(CAS: 845256-65-7)

MK-0731 is a synthetic small molecule with potential antineoplastic activity. MK0731 selectively inhibits kinesin spindle protein (KSP), which may result in the...

CAS 72926-24-0 K-858

K-858
(CAS: 72926-24-0)

K-858 is a novel inhibitor of mitotic kinesin Eg5 and antitumor agent, induces cell death in cancer cells. K858 blocked centrosome separation, activated the spi...

CAS 336113-53-2 Ispinesib

Ispinesib
(CAS: 336113-53-2)

Ispinesib is a synthetic small molecule, derived from quinazolinone, with antineoplastic properties. Ispinesib selectively inhibits the mitotic motor protein, k...

CAS 885060-08-2 ARRY-520 R enantiomer

ARRY-520 R enantiomer
(CAS: 885060-08-2)

ARRY-520 R enantiomer is the R form of ARRY-520, which is a synthetic, small molecule kinesin spindle protein (KSP) inhibitor. ARRY-520 had low nanomolar antipr...

CAS 910634-41-2 Litronesib

Litronesib
(CAS: 910634-41-2)

litronesib, also known as LY2523355, is an inhibitor of the kinesin-related motor protein Eg5 with potential antineoplastic activity. Litronesib selectively inh...

Chemical Structure

CAS 885060-09-3 Filanesib

Quick Inquiry

Verification code

Featured Items